An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy

Bibliography

• Dunn DW, Austin JK. Differential diagnosis and treatment of psychiatric disorders in children and adolescents with epilepsy. Epilepsy Behav 2004;5(Suppl 3):10-7
   PubMed Web of Science ®Google Scholar
• Dunn DW, Austin JK, Harezlak J, Ambrosius WT. ADHD and epilepsy in childhood. Dev Med Child Neurol 2003;45(1):50-4
   PubMed Web of Science ®Google Scholar
• Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 2004;114(5):E541-E547
   PubMed Web of Science ®Google Scholar
• Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998;279(14):1100-7
   PubMed Web of Science ®Google Scholar
• Dopheide J. A calming influence. an analysis of ADHD treatments. In: Pharmacy Times 2006
   Google Scholar
• Hemmer SA, Pasternak JF, Zecker SG, Trommer BL. Stimulant therapy and seizure risk in children with ADHD. Pediatr Neurol 2001;24(2):99-102
   PubMed Web of Science ®Google Scholar
• Weber P, Lutschg J. Methylphenidate treatment. Pediatr Neurol 2002;26(4):261-6
   PubMed Web of Science ®Google Scholar
• Physician's Desk Reference 2007. Montvale, NJ; Thomson PDR, 2007
   Google Scholar
• Eckerman DA, Moy SS, Perkins AN, et al. Enantioselective behavioral effects of threo-methylphenidate in rats. Pharmacol Biochem Behav 1991;40(4):875-80
   PubMed Web of Science ®Google Scholar
• Srinivas NR, Hubbard JW, Quinn D, Midha KK. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther 1992;52(5):561-8
   PubMed Web of Science ®Google Scholar
• Patrick KS, Caldwell RW, Ferris RM, Breese GR. Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther 1987;241(1):152-8
   PubMed Web of Science ®Google Scholar
• Ding YS, Gatley SJ, Thanos PK, et al. Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration. Synapse 2004;53(3):168-75
   PubMed Web of Science ®Google Scholar
• Kuczenski R, Segal DS. Effects of mthylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 1997;68(5):2032-7
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001;21(2)
   Google Scholar
• Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998;94(1):127-52
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, Ding YS. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57(11):1410-5
   PubMed Web of Science ®Google Scholar
• Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995;52(6):456-63
   PubMed Web of Science ®Google Scholar
• Kiyatkin EA, Rebec GV. Dopaminergic modulation of glutamate-induced excitations of neurons in the neostriatum and nucleus accumbens of awake, unrestrained rats. J Neurophysiol 1996;75(1):142-53
   PubMed Web of Science ®Google Scholar
• Babington RG, Wedeking PW. The pharmacology of seizures induced by sensitization with low intensity brain stimulation. Pharmacol Biochem Behav 1973;1(4):461-7
   PubMedGoogle Scholar
• Chamberlain RW. Letter: convulsions and ritalin? Pediatrics 1974;54(5):658-9
   PubMedGoogle Scholar
• Feeney DJ, Klykylo WM. Medication-induced seizures. J Am Acad Child Adolesc Psychiatry 1997;36(8):1018-9
   PubMed Web of Science ®Google Scholar
• Tavakoli SA, Gleason OC. Seizures associated with venlafaxine, methylphenidate, and zolpidem. Psychosomatics 2003;44(3):262-4
   PubMed Web of Science ®Google Scholar
• Semrud-Clikeman M, Wical B. Components of attention in children with complex partial seizures with and without ADHD. Epilepsia 1999;40(2):211-5
   PubMed Web of Science ®Google Scholar
• McBride MC, Wang DD, Torres CF. Methylphenidate in therapeutic doses does not lower seizure threshold. Ann Neurol 1986:428
   Google Scholar
• Wroblewski BA, Leary JM, Phelan AM, Whyte J, Manning K. Methylphenidate and seizure frequency in brain injured patients with seizure disorder. J Clin Psychiatry 1992;53(3):86-9
   PubMed Web of Science ®Google Scholar
• Gonzalez-Heydrich J, Hsin O, Hickory M, et al. Comparisons of response to stimulant preparations in pediatric epilepsy. Washington, DC: American Academy of Child and Adolescent Psychiatry Meeting, 2004
   Google Scholar
• Moore JL, McAuley JW, Long L, Bornstein R. An evaluation of the effects of methylphenidate on outcomes in adult epilepsy patients. Epilepsy Behav 2002;3(1):92-5
   PubMed Web of Science ®Google Scholar
• Van Der Feltz-Cornelis CM, Aldenkamp AP. Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment trial. Epilepsy Behav 2006;8(3):659-62
   PubMed Web of Science ®Google Scholar
• Gross-Tsur V, Manor O, Van Der Meere J, et al. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr 1997;130(4):670-4
   PubMed Web of Science ®Google Scholar
• Finck S, Metz-Lutz MN, Becache E, et al. Attention-deficit hyperactivity disorder in epileptic children: a new indication for methylphenidate? Ann Neurol 1995;38:520
   Google Scholar
• Gucuyener K, Erdemoglu AK, Senol S, et al. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 2003;18(2):109-12
   PubMed Web of Science ®Google Scholar
• Lubar JF, White JN Jr, Swartwood MO, Swartwood JN. Methylphenidate effects on global and complex measures of EEG. Pediatr Neurol 1999;21(3):633-7
   PubMed Web of Science ®Google Scholar
• Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998;16(7):2522-7
   PubMed Web of Science ®Google Scholar
• Feldman H, Crumrine P, Handen BL, et al. Methylphenidate in children with seizures and attention-deficit disorder. Am J Dis Child 1989;143(9):1081-6
   PubMedGoogle Scholar
• Gonzalez-Heydrich J, Whitney J, Hsin O, et al. Efficacy of OROS®MPH for treatment of ADHD plus epilepsy. San Diego: American Academy of Child and Adolescent Psychiatry Meeting, 2006
   Google Scholar
• Garrettson LK, Perel JM, Dayton PG. Methylphenidate interaction with both anticonvulsants and ethyl biscoumacetate. JAMA 1969;207(11):2053-6
   PubMed Web of Science ®Google Scholar
• Kupferberg HJ, Jeffery W, Hunninghake DB. Effect of methylphenidate on plasma anticonvulsant levels. Clin Pharmacol Ther 1972;13(2):201-4
   PubMedGoogle Scholar
• Ghofrani M. Possible phenytoin-methylphenidate interaction. Dev Med Child Neurol 1988;30(2):267-8
   PubMed Web of Science ®Google Scholar
• Mirkin BL, Wright F. Drug interactions: effect of methylphenidate on the disposition of diphenylhydantoin in man. Neurology 1971;21(11):1123-8
   PubMed Web of Science ®Google Scholar
• Gara L, Roberts W. Adverse response to methylphenidate in combination with valproic acid. J Child Adolesc Psychopharmacol 2000;10(1):39-43
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 2001;40(10):753-72
   PubMed Web of Science ®Google Scholar
• Schaller JL, Behar D. Carbamazepine and methylphenidate in ADHD. J Am Acad Child Adolesc Psychiatry 1999;38(2):112-3
   PubMed Web of Science ®Google Scholar
• Behar D, Schaller J, Spreat S. Extreme reduction of methylphenidate levels by carbamazepine. J Am Acad Child Adolesc Psychiatry 1998;37(11):1128-9
   PubMedGoogle Scholar
• Gonzalez-Heydrich J, Whitney J, Hsin O, et al. Tolerability of OROS® MPH in pediatric epilepsy plus attention-deficit/hyperactivity disorder (ADHD). Toronto: Meeting of the American Academy of Child and Adolescent Psychiatry, 2005
   Google Scholar
• Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46(7):894-921
   PubMed Web of Science ®Google Scholar